Navigation Links
ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

ZURICH, Switzerland, Jan. 9/PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of the Phase I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, placebo-controlled Phase I/IIa clinical study is designed to investigate the safety, tolerability and efficacy on pain with ESBA105 applied locally via intra-articular administration to patients with severely painful OA of the knee. The multicenter study is initiated at various sites across Switzerland.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "As of today, no disease-modifying osteoarthritis drug exists, which is the key unmet need. OA is being increasingly recognized as driven by episodes of local inflammation and thus, TNF alpha represents a highly promising target. TNF alpha is excessively generated in OA by chondrocytes, which are located within the cartilage. Thus, to achieve disease-modifying activity, it is expected that the drug needs to penetrate into the cartilage, which cannot be achieved by the currently marketed TNF inhibitors. With ESBA105, we observe a very efficient penetration into the cartilage. By that, inhibiting TNF alpha can address the major aspects of OA therapy: signs and symptoms and cartilage degeneration. If clinically successful, ESBA105 is uniquely positioned to fill the need to treat OA with a safe and effective local therapy. A disease-modifying drug would revolutionize the treatment of this debilitating disease."

TNF alpha is a cytokine and a key player in inflammation, and has been identified as a major contributor to pain (signs and symptoms) and cartilage degeneration (structure modification), the main clinical characteristics of OA. Current treatments for OA comprise mainly of non-steroidal anti-inflammatory drugs and intra-articular injections of hyaluronic acids and corticosteroids. These treatments, however, are restricted to pain management, but do not address cartilage degeneration. Blocking TNF alpha offers the opportunity to attack both aspects, managing pain and structure modification. Because of the degenerative nature of OA, every year more than 130,000 knee replacement surgeries are performed in the U.S. alone. Similar numbers are seen in Europe and other major markets.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, added, "Antibody fragments have a number of advantages over whole antibodies, resulting from their smaller molecular weight. In fact, they are capable of penetrating tissues not accessible to conventional monoclonal antibodies, such as avascularized tissues like cartilage. By delivering high amounts of ESBA105 directly to the affected joint, the antibody fragment quickly and efficiently distributes to the relevant sites in the joint. On the other hand, based on the local delivery and the short systemic half life, systemic exposure of ESBA105 is very low as compared to traditional TNF alpha inhibitors. This is a crucial point in OA, which is a non-life-threatening, rather local disease. Therefore, systemic suppression of TNF alpha, as achieved by marketed TNF alpha inhibitors and associated with various safety issues, is not justified for osteoarthritis patients. The molecular properties of ESBA105 are tailored to the needs of patients suffering from local disease. In this initial clinical trial, we will focus on safety and effects on signs and symptoms. However, the ultimate goal for ESBA105 in OA is disease modification."

About Osteoarthritis

OA is a clinical syndrome of severe joint pain and dysfunction associated with joint degeneration, in particular cartilage loss. More than 70 million people in the seven major pharmaceutical markets and 40 million in the U.S. alone are afflicted with OA. The disease occurs more frequently with age and recent data show the OA market to be growing by three percent annually. At this rate the U.S. patient population will grow to 60 million by 2020.

About ESBATech's antibody fragment platform technology

ESBATech is the first and only company to date that has successfully screened and characterized the entire human pool (1.5 million) of naturally occurring variable immunoglobulin (VH and VL) domains to select highly stable, soluble and monomeric single-chain antibody fragment frameworks. ESBATech's unique, scientific approach to stabilize monomeric, single-chain antibody fragments (scFvs) using its proprietary fully-human antibody fragment frameworks has elucidated the drug-like properties of these proprietary scFvs. The company is advancing a pipeline of novel antibody fragment therapeutics for topical and/or local delivery, to ensure safe and convenient patient therapy.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The Company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. The Company focuses on three franchises: ophthalmology, rheumatology and respiratory. In ophthalmology, the Company has successfully completed clinical Phase I development of ESBA105 administered topically via eye drops for inflammatory eye diseases.

Current venture investors include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest and VI Partners. For more information about ESBATech, please visit,

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
5. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
6. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
7. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
8. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
Post Your Comments:
(Date:12/1/2015)... -- WellStar Health System has signed a definitive agreement ... Healthcare,s five metro Atlanta hospitals. ... following the conclusion of the due diligence period. WellStar ... patient safety programs that have resulted in increased quality ... --> --> With ever-changing ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015  CytoSorbents ... immunotherapy leader, commercializing its CytoSorb® blood purification technology ... around the world, today announced that Dr. ... is scheduled to participate in the LD Micro ... Discovery One-on-One Conference, both of which will be ...
(Date:12/1/2015)... -- Royal Philips  (NYSE: PHG, AEX: ... software that produces high-contrast images for all anatomies in ... at the 2015 Radiological Society of North America ... first digital imaging solution providing grid-like contrast improvement and ... and supports "first-time-right imaging" by decreasing the need for ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Royal River Natural Foods — a locally-owned, ... post-menopausal women who took the nutritional supplement creatine, along with resistance training for a ... not take creatine. , The report is part of the December 2015 issue of ...
(Date:12/1/2015)... ... 01, 2015 , ... Baptist Medical Center Jacksonville has implanted ... only hospital in the region providing what is known as the world’s smallest ... were revealed recently at a medical conference and published in The New England ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 -- ... the company’s growing product line of food safety and seafood fraud prevention tools. ... nerka) – allow InstantLabs to offer fast, reliable species identification for the four ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... amputations in the United States. Podiatrists are well aware that psychology-based patient non-compliance ... behaviors) are often catastrophic contributors to diseases of the diabetic foot. The ...
(Date:12/1/2015)... Francisco, CA (PRWEB) , ... December 01, 2015 ... ... Behavioral Health Center of Excellence (BHCOE) today announced that the organization has awarded ... in San Francisco, with a Distinguished Award. The award celebrates exceptional special needs ...
Breaking Medicine News(10 mins):